On day 5, the decrease in viral load from baseline was greater in the simnotrelvir group versus placebo group
Bivalent COVID-19 Shot Effective for Preventing Thromboembolic Events
Findings seen for adults aged 65 years and older and for those aged 18 years and older with end-stage renal disease
Bivalent COVID-19 Shot Effective for Preventing Thromboembolic Events
Findings seen for adults aged 65 years and older and for those aged 18 years and older with end-stage renal disease
Preexisting Conditions Seen in All Patients With Tachycardia After COVID-19 Vaccine
Reduced heart rate variability observed in patients with postvaccination postural orthostatic tachycardia syndrome
Nirmatrelvir During Acute SARS-CoV-2 Does Not Reduce Risk for Long COVID
No association seen for rebound symptoms or test positivity with symptoms of long COVID
COVID-19 Pandemic at a Tipping Point: WHO
Organization’s International Health Regulations Emergency Committee met last week to discuss COVID-19
Post-COVID-19 Brain Health Impaired Versus Healthy Controls
However, brain health is comparable to that of patients hospitalized for other medical conditions of similar severity
Nearly Half of U.S. COVID-19 Cases Now Caused by JN.1 Variant
The speed at which the JN.1 variant has spread this month suggests it may spread more easily and be better at evading immune system
SARS-CoV-2 Rebound Rate Similar With, Without Oral Antivirals
Second study shows similar rates of SARS-CoV-2 RNA shedding and viral rebound for those receiving nirmatrelvir/ritonavir or placebo
Many U.S. Nursing Home Residents Have Not Been Vaccinated for Flu, COVID-19, or RSV for 2023-24
Second study shows that 42.2 and 18.3 percent of individuals aged 18 years and older reported receiving flu, updated COVID-19 shots